Activated Factor VIIA Can Correct Severe Coagulopathy in Pediatric Patients with VOD
Background: Veno-occlusive disease (VOD) can be a life-threatening complication of allogeneic and autologous hematopoietic stem cell transplant (HSCT). The pathologic process affects multiple organs including liver, lung, kidney and the coagulation system. The severity of the coagulopathy varies considerably between patients. Few data exist on the best methods to correct coagulation parameters and reduce the risk of bleeding in patients with VOD. This is critically important since the contraindication for defibrotide treatment includes uncontrolled bleeding.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Sandeepkumar Kuril, Shayla Bergmann, Leah Judd, Amanda Littleton, Julie Heh, Michelle Hudspeth, Jennifer Joi Jaroscak Source Type: research
More News: Biology | Bleeding | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Lung Transplant | Pediatrics | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Urology & Nephrology